Avalo Therapeutics, Inc.
AVTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAvalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. With a market capitalization of $371.7M, it sits in small-cap territory. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Market Cap
$371.7M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-2.56
EPS (TTM)
$-4.31
EPS (Fwd)
$-2.71
ROE
-36.3%
ROA
-18.5%
Cash
$400.3M
Total Debt
$242,000
Free CF
-$23.3M
52W Change
-61.5%
Annual Financials
Cash vs Debt
Where AVTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AVTX finished 30.01% below its 150-day moving average ($16.56) and 29.37% below its 200-day moving average ($16.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVTX overbought or oversold?
At the October 20, 2026 close, AVTX's RSI(14) was 13.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $400.3M in cash comfortably exceeding the $242K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$23.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -36.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.1M (2022) to $59K (2025), a 100% decline worth watching.
With a beta below 0.7, Avalo Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, AVTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Avalo Therapeutics, Inc. and its sector.